Overview
Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year
Company plans new Phase 3 trial for LYR-210, aiming for NDA submission
Cash reserves expected to fund operations into Q3 2026
Outlook
Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission
Company anticipates cash reserves to fund operations until Q3 2026
Result Drivers
R&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction
G&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$25,000
Q3 EPS
-$3.38
Q3 Net Income
-$5.98 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 81.6% above its November 11 closing price of $4.24
Press Release: ID:nGNX13nXTP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
